Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.45 is 43% below its 3-year average of -0.31, around the middle of its 3-year range (-1.48–0.38).
491.30% below its 12-month average of 0.12.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.09.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 33 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:36:32.277Z. Historical observations retain their original dates. Historical series through 2026-05-07.
EARNINGS PER SHARE (EPS)
-0.45
EARNINGS PER SHARE (EPS) AVG TTM
0.12
EARNINGS PER SHARE (EPS) AVG 3Y
-0.31
EARNINGS PER SHARE (EPS) AVG 5Y
-0.31
EARNINGS PER SHARE (EPS) AVG 10Y
-1.04
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-491.30%
CURRENT VS 3Y AVG
-43.12%
CURRENT VS 5Y AVG
-43.12%
CURRENT VS 10Y AVG
+56.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CytomX Therapeutics, Inc.
Market Cap
$551.88M
Earnings Per Share (EPS)
-0.45
TTM Avg
0.12
3Y Avg
-0.31
5Y Avg
-0.31
Market Cap
$552.54M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.57
3Y Avg
-1.57
5Y Avg
-1.57
Market Cap
$549.58M
Earnings Per Share (EPS)
-0.58
TTM Avg
-1.12
3Y Avg
-1.21
5Y Avg
-1.27
Market Cap
$569.15M
Earnings Per Share (EPS)
-3.68
TTM Avg
-3.44
3Y Avg
-2.54
5Y Avg
-10.12
Market Cap
$560.00M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$562.50M
Earnings Per Share (EPS)
2.13
TTM Avg
0.97
3Y Avg
0.08
5Y Avg
-0.20
Market Cap
$563.97M
Earnings Per Share (EPS)
-0.65
TTM Avg
-0.64
3Y Avg
-0.63
5Y Avg
-1.00
Market Cap
$534.40M
Earnings Per Share (EPS)
0.01
TTM Avg
0.08
3Y Avg
-2.02
5Y Avg
-4.00
Market Cap
$528.95M
Earnings Per Share (EPS)
-7.58
TTM Avg
-39.00
3Y Avg
-56.28
5Y Avg
-76.67
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | $551.88M | -0.45 | 0.12 | -0.31 | -0.31 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.54M | N/A | -1.57 | -1.57 | -1.57 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.58M | -0.58 | -1.12 | -1.21 | -1.27 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $569.15M | -3.68 | -3.44 | -2.54 | -10.12 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $562.50M | 2.13 | 0.97 | 0.08 | -0.20 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $563.97M | -0.65 | -0.64 | -0.63 | -1.00 |
| Delcath Systems, Inc. (DCTH)vs › | $534.40M | 0.01 | 0.08 | -2.02 | -4.00 |
| Crescent Biopharma, Inc. (CBIO)vs › | $528.95M | -7.58 | -39.00 | -56.28 | -76.67 |
| OrthoPediatrics Corp. (KIDS)vs › | $580.22M | -1.68 | -1.67 | -1.05 | -1.14 |
Trailing EPS (TTM)
$-0.45
Forward EPS (Est.)
$-0.38
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.15 |
| 2024-12-31 | 0.38 |
| 2023-12-31 | -0.01 |
| 2022-12-31 | -1.48 |
| 2019-12-31 | -2.26 |
| 2018-12-31 | -2.03 |
| 2017-12-31 | -1.16 |
| 2016-12-31 | -1.63 |
| 2015-12-31 | -1.00 |
| 2014-12-31 | -0.87 |
| 2013-12-31 | -15.32 |
